Latest Breaking News On - Ts lgvn us54303l1044 - Page 1 : comparemela.com

MIAMI, Nov. 07, 2022 Longeveron Inc. , a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that the Company will release its third. | November 7, 2022

United statesElsie yauStern ir incLongeveron or companyGlobenewswire incLongeveron incDial in numberLocations dial in numberReplay dial in numberHypoplastic left heart syndromeLongeveron inc stock exchangePress releaseTs lgvn us54303l1044